Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Aclaris Therapeutics
Thumbnail
November 22, 2021

The bubble bursts for biotech stocks

After a frothy couple of years, biotechs are no longer seeing big boosts from clinical data.

Thumbnail
September 02, 2021

Jaks capped in arthritis – but the FDA might not be finished

The US regulator’s restrictions spell trouble for the Jak inhibitor class – though there will be beneficiaries.

Article image
Vantage logo
June 09, 2021

Aclaris’s second crack at a topical Jak

But, with Incyte close to market and several big players moving forward, Aclaris’s project will need to stand out from the pack.

Article image
Vantage logo
April 19, 2021

Stock market correction sends biopharma back to the start of 2021

Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.

Article image
Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

It's official: dramatic share price jumps in response to clinical data have become more common.

Article image
Vantage logo
January 19, 2021

Aclaris MK2 bears fruit

Aclaris takes a step towards an oral rheumatoid arthritis therapy.

Article image
Vantage logo
October 04, 2019

Japanese drugmakers stand out at the nine-month mark

Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.

Article image
Vantage logo
September 03, 2019

Concert squares up to Pfizer in alopecia Jak bout

Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.

Article image
Vantage logo
July 31, 2019

Aclaris’s alopecia Jak might not be worth its Salt

Vantage logo
July 03, 2019

Share price catalysts: June 2019

Article image
Vantage logo
June 17, 2019

Incyte hopes its cream can rise to the top

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.